Protocol Ledger

NCT05186818 · Phase III · COMPLETED

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

Interventional Phase III clinical trial protocol NCT05186818 sponsored by Cytokinetics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-01 Enrollment: 282 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05186818
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)282 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05186818
Protocol FieldVerified Registry Value
NCT IdentifierNCT05186818
Consolidated Lead SponsorCytokinetics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment282 participants (ACTUAL)
Registered Start Date2022-02-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI